In a report released today, Chad Messer from Needham maintained a Buy rating on Gamida Cell (GMDA), with a price target of $17.00. The company’s shares closed last Tuesday at $5.80.
According to TipRanks.com, Messer is a 4-star analyst with an average return of 9.0% and a 45.5% success rate. Messer covers the Healthcare sector, focusing on stocks such as Phasebio Pharmaceuticals, Aeglea Biotherapeutics, and Ionis Pharmaceuticals.
Currently, the analyst consensus on Gamida Cell is a Strong Buy with an average price target of $16.25.
See today’s analyst top recommended stocks >>
The company has a one-year high of $7.70 and a one-year low of $2.60. Currently, Gamida Cell has an average volume of 251.2K.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Gamida Cell Ltd. is a clinical stage biopharmaceutical company engaging in the development of cell therapies to cure blood cancer and rare serious hematologic diseases. The company was founded by Tony Peled and Menashe Levy in 1998 and is headquartered in Jerusalem, Israel.
